Johnson and Johnson

The NIH Begins Trial on Mixing COVID Vaccine Boosters

A trial funded by the NIH has entered Phase 1/2 testing to study COVID-19 vaccine boosters from different manufacturers on fully vaccinated adults. While it has not been determined whether boosters will be necessary, Dr. Fauci has stated that “we need to prepare for the possibility… to counter waning immunity and to keep pace with an evolving virus”

Read More »

Johnson & Johnson’s COVID-19 Vaccine Has Been Resumed

This past Friday, the CDC lifted the pause on Johnson & Johnson’s COVID-19 vaccine usage. During this pause, which was announced on April 13, the CDC confirmed an additional 9 cases of women developing thrombosis with thrombocytopenia syndrome (TTS) blood clots with low platelet count after receiving the J&J vaccine. The pause was initiated after 6 cases were presumed to be linked to the J&J vaccine. 13 of the 15 women were between the ages of 18-49.

Read More »

Americans 16+ Are Eligible for COVID-19 Vaccine

As of yesterday, Monday, April 19, all Americans ages 16+ are eligible to get the COVID-19 vaccine. According to the CDC’s COVID Data Tracker, over 132 million Americans have received one dose of the vaccine, and over 85 million have been fully vaccinated against the novel coronavirus. This 85 million figure represents 64.9% of Americans 65+ years of age. 

Read More »

Adenovirus Vaccines Shown to Have Hematological Side Effect Concerns

As of yesterday, 6.8 million doses of the Johnson & Johnson (Janssen) vaccine have been administered throughout the United States. As of today, the CDC and FDA announced that they are reviewing six reported cases of a rare severe type of blood clot in individuals after receiving the vaccine” and are recommending a pause in the use of the single-dose Johnson & Johnson COVID-19 vaccine until a more thorough investigation can be conducted. The CDC will convene a meeting of the Advisory Committee on immunization practices (ACIP) tomorrow, Wednesday, April 14th, to further review these cases and assess their potential significance, and this analysis will also be reviewed by the FDA.

Read More »
Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.